These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 24457590)

  • 21. Multicenter, randomized, double-blind, active comparator and placebo-controlled trial of a corticotropin-releasing factor receptor-1 antagonist in generalized anxiety disorder.
    Coric V; Feldman HH; Oren DA; Shekhar A; Pultz J; Dockens RC; Wu X; Gentile KA; Huang SP; Emison E; Delmonte T; D'Souza BB; Zimbroff DL; Grebb JA; Goddard AW; Stock EG
    Depress Anxiety; 2010 May; 27(5):417-25. PubMed ID: 20455246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Brown ES; Howard C; Khan DA; Carmody TJ
    Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Repetitive transcranial magnetic stimulation (rTMS) in combination with escitalopram in patients with treatment-resistant major depression: a double-blind, randomised, sham-controlled trial.
    Bretlau LG; Lunde M; Lindberg L; Undén M; Dissing S; Bech P
    Pharmacopsychiatry; 2008 Mar; 41(2):41-7. PubMed ID: 18311683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Citalopram and escitalopram in the treatment of major depressive disorder: a pooled analysis of 3 clinical trials.
    Li H; Li T; Li G; Luo J
    Ann Clin Psychiatry; 2014 Nov; 26(4):281-7. PubMed ID: 25401715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Escitalopram versus placebo in the treatment of dysthymic disorder.
    Hellerstein DJ; Batchelder ST; Hyler S; Arnaout B; Toba C; Benga I; Gangure D
    Int Clin Psychopharmacol; 2010 May; 25(3):143-8. PubMed ID: 21811192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Escitalopram and enhancement of cognitive recovery following stroke.
    Jorge RE; Acion L; Moser D; Adams HP; Robinson RG
    Arch Gen Psychiatry; 2010 Feb; 67(2):187-96. PubMed ID: 20124118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP; Huusom AK; Florea I; Baekdal T; Sarchiapone M
    Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Escitalopram versus paroxetine for social anxiety disorder: an analysis of efficacy for different symptom dimensions.
    Stein DJ; Andersen EW; Lader M
    Eur Neuropsychopharmacol; 2006 Jan; 16(1):33-8. PubMed ID: 16014329
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Debunking the placebo effect in depression: the effect of patient and investigator expectation on escitalopram efficacy.
    Nehama Y; Rabinowitz I; Baruch Y; Mandel A; Lurie I; Barak Y
    Int Clin Psychopharmacol; 2014 Mar; 29(2):106-10. PubMed ID: 24172161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No evidence for an anti-inflammatory effect of escitalopram intervention in healthy individuals with a family history of depression.
    Haastrup E; Knorr U; Erikstrup C; Kessing LV; Ullum H
    J Neuroimmunol; 2012 Feb; 243(1-2):69-72. PubMed ID: 22244574
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L; Andersen HF; Reines EH
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superiority of escitalopram to paroxetine in the treatment of depression.
    Kasper S; Baldwin DS; Larsson Lönn S; Boulenger JP
    Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropsychological functioning in young subjects with generalized anxiety disorder with and without pharmacotherapy.
    Tempesta D; Mazza M; Serroni N; Moschetta FS; Di Giannantonio M; Ferrara M; De Berardis D
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():236-41. PubMed ID: 23796524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B; Moore N; Verdoux H; Auray JP
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
    Olié JP; Tonnoir B; Ménard F; Galinowski A
    Depress Anxiety; 2007; 24(5):318-24. PubMed ID: 17041922
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Which Patients Are Prescribed Escitalopram?: Predictors for Escitalopram Prescriptions and Functional Outcomes among Patients with Acute Ischemic Stroke.
    Kim J; Kim Y
    Int J Environ Res Public Health; 2018 May; 15(6):. PubMed ID: 29843379
    [TBL] [Abstract][Full Text] [Related]  

  • 37. What are the optimal treatment courses for geriatric anxiety, and how do we find out?
    Barlow DH; Comer JS
    Am J Psychiatry; 2013 Jul; 170(7):707-11. PubMed ID: 23680970
    [No Abstract]   [Full Text] [Related]  

  • 38. Increased frequency of first-episode poststroke depression after discontinuation of escitalopram.
    Mikami K; Jorge RE; Moser DJ; Arndt S; Jang M; Solodkin A; Small SL; Fonzetti P; Hegel MT; Robinson RG
    Stroke; 2011 Nov; 42(11):3281-3. PubMed ID: 21868736
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Correlation between denial of illness and executive function following stroke: a pilot study.
    Narushima K; Moser DJ; Robinson RG
    J Neuropsychiatry Clin Neurosci; 2008; 20(1):96-100. PubMed ID: 18305291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical characteristics of post-stroke anxiety disorders].
    Petrova EA; Savina MA; Kontsevoĭ VA; Skvortsova VI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(9):12-6. PubMed ID: 23235406
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.